Serum sulfatide abnormality is associated with increased oxidative stress in hemodialysis patients

Hemodialysis International

Volumn 19, Issue 3, 2015, Pages 429-438

  Yuzhe, Huang ^a,b   Kamijo, Yuji ^a,c   Hashimoto, Koji ^c   Harada, Makoto ^a,c   Kanno, Taro ^c   Sugiyama, Eiko ^a,d   Kyogashima, Mamoru ^e   Oguchi, Tomomasa ^f   Nakajima, Takero ^a   Kanno, Yutaka ^g   Aoyama, Toshifumi ^a  

^a SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Nagano Prefectural College   (Japan)

^e NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

^f Aizawa Hospital   (Japan)

^g Kanno Dialysis and Vascular Access Clinic   (Japan)

Author keywords

Cardiovascular disease; Hemodialysis; Malondialdehyde; Oxidative stress; Serum sulfatide level

Indexed keywords

BIOLOGICAL MARKER; SULFATIDE;

ADULT; ADVERSE EFFECTS; AGED; BLOOD; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; FEMALE; HEMODIALYSIS; HUMAN; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; RENAL DIALYSIS; SULFOGLYCOSPHINGOLIPIDS;

EID: 84934442057     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/hdi.12270     Document Type: Article

References (22)

1. Ishizuka I. Chemistry and functional distribution of sulfoglycolipids. Prog Lipid Res. 1997; 36:245-319.
2. Hara A, Taketomi T. Occurrence of sulfatide as a major glycosphingolipid in WHHL rabbit serum lipoproteins. J Biochem. 1987; 102:83-92.
3. Zhu XH, Hara A, Taketomi T. The existence of galactosylceramide I3-sulfatide in serums of various mammals and its anticoagulant activity. J Biochem. 1991; 110:241-245.
4. Takahashi T, Suzuki T. Role of sulfatide in normal and pathological cells and tissues. J Lipid Res. 2012; 53:1437-1450.
5. Hara A, Taketomi T. Characterization and changes of glycosphingolipids in the aorta of the Watanabe hereditable hyperlipidemic rabbit. J Biochem. 1991; 109:904-908.
6. Hara A, Uemura K, Taketomi T. Sulfatide prolongs blood-coagulation time and bleeding time by forming a complex with fibrinogen. Glycoconj J. 1996; 13:187-194.
7. Kyogashima M, Onaya J, Hara A, Taketomi T. Contradictory functions of sulfatide in the blood coagulation system as coagulant and anticoagulant. Acta Biochim Pol. 1998; 45:493-499.
8. Sarnak MJ, Levey AS, Schoolwerth AC, etal. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003; 108:2154-2169.
9. Locatelli F, Marcelli D, Conte F, etal. Cardiovascular disease in chronic renal failure: The challenge continues. Nephrol Dial Transplant. 2000; 15:69-80.
10. Hu R, Li G, Kamijo Y, etal. Serum sulfatides as a novel biomarker for cardiovascular disease in patients with end-stage renal failure. Glycoconj J. 2007; 24:565-571.
11. Zhang X, Nakajima T, Kamijo Y, etal. Acute kidney injury induced by protein-overload nephropathy down-regulates gene expression of hepatic cerebroside sulfo-transferase in mice, resulting in reduction of liver and serum sulfatides. Biochem Biophys Res Commun. 2009; 390:1382-1388.
12. Kanbe H, Kamijo Y, Nakajima T, etal. Chronic ethanol consumption decreases serum sulfatide levels by suppressing hepatic cerebroside sulfotransferase expression in mice. Arch Toxicol. 2014; 88:367-379.
13. Wang L, Kamijo Y, Matsumoto A, etal. Kidney transplantation recovers the reduction level of serum sulfatide in ESRD patients via processes correlated to oxidative stress and platelet count. Glycoconj J. 2011; 28:125-135.
14. Kamijo Y, Wang L, Matsumoto A, etal. Long-term improvement of oxidative stress via kidney transplantation ameliorates serum sulfatide levels. Clin Exp Nephrol. 2012; 16:959-967.
15. Lekawanvijit S, Kompa AR, Wang BH, Kelly DJ, Krum H. Cardiorenal syndrome: The emerging role of protein-bound uremic toxins. Circ Res. 2012; 111:1470-1483.
16. Coombes JS, Fassett RG. Antioxidant therapy in hemodialysis patients: A systematic review. Kidney Int. 2012; 81:233-246.
17. Hara A, Radin NS. Lipid extraction of tissues with a low-toxicity solvent. Anal Biochem. 1978; 90:420-426.
18. Li G, Hu R, Kamijo Y, etal. Establishment of a quantitative, qualitative, and high-throughput analysis of sulfatides from small amounts of sera by matrix-assisted laser desorption ionization-time of flight mass spectrometry. Anal Biochem. 2007; 362:1-7.
19. Aoyama T, Yamano S, Waxman DJ, etal. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem. 1989; 264:10388-10395.
20. Nakai S, Watanabe Y, Masakane I, etal. Overview of regular dialysis treatment in Japan (as of 31 December 2011). Ther Apher Dial. 2013; 17:567-611.
21. Nakajima T, Kamijo Y, Yuzhe H, etal. Peroxisome proliferator-activated receptor α mediates enhancement of gene expression of cerebroside sulfotransferase in several murine organs. Glycoconj J. 2013; 30:553-560.
22. Lopez-Hernandez FJ, Lopez-Novoa JM. Potential utility of PPARalpha activation in the prevention of ischemic and drug-induced acute renal damage. Kidney Int. 2009; 76:1022-1024.